 Joshua Wisell
Concepts (213)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Skin Neoplasms | 9 | 2026 | 847 | 1.950 |
Why?
| | Sporotrichosis | 2 | 2018 | 6 | 1.150 |
Why?
| | Immunocompromised Host | 3 | 2019 | 201 | 1.150 |
Why?
| | Diagnostic Errors | 2 | 2016 | 175 | 0.780 |
Why?
| | Acquired Immunodeficiency Syndrome | 2 | 2018 | 231 | 0.650 |
Why?
| | Plasmablastic Lymphoma | 1 | 2019 | 8 | 0.600 |
Why?
| | Itraconazole | 1 | 2018 | 7 | 0.580 |
Why?
| | Dermatomycoses | 1 | 2018 | 8 | 0.580 |
Why?
| | Paget Disease, Extramammary | 1 | 2018 | 4 | 0.560 |
Why?
| | Opportunistic Infections | 1 | 2018 | 45 | 0.560 |
Why?
| | Carcinoma, Merkel Cell | 1 | 2017 | 16 | 0.530 |
Why?
| | Biomarkers, Tumor | 4 | 2026 | 1313 | 0.520 |
Why?
| | Transplant Recipients | 1 | 2019 | 180 | 0.520 |
Why?
| | Pathology, Surgical | 1 | 2016 | 6 | 0.500 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 1 | 2019 | 192 | 0.490 |
Why?
| | Frozen Sections | 1 | 2016 | 24 | 0.490 |
Why?
| | Melanoma | 4 | 2017 | 760 | 0.480 |
Why?
| | Neurodermatitis | 1 | 2015 | 1 | 0.460 |
Why?
| | Foot Dermatoses | 1 | 2015 | 4 | 0.460 |
Why?
| | Acanthosis Nigricans | 1 | 2015 | 4 | 0.460 |
Why?
| | Leprosy, Lepromatous | 2 | 2025 | 8 | 0.460 |
Why?
| | Minocycline | 1 | 2015 | 22 | 0.460 |
Why?
| | Acne Vulgaris | 1 | 2015 | 25 | 0.450 |
Why?
| | Hyperpigmentation | 1 | 2015 | 27 | 0.450 |
Why?
| | Uveitis, Anterior | 2 | 2025 | 27 | 0.450 |
Why?
| | Quality Assurance, Health Care | 1 | 2016 | 336 | 0.420 |
Why?
| | Granular Cell Tumor | 1 | 2014 | 8 | 0.410 |
Why?
| | SOXE Transcription Factors | 1 | 2014 | 22 | 0.410 |
Why?
| | Proto-Oncogene Proteins B-raf | 3 | 2026 | 225 | 0.400 |
Why?
| | Scalp | 1 | 2013 | 37 | 0.390 |
Why?
| | Decidua | 1 | 2012 | 22 | 0.370 |
Why?
| | Hemangioendothelioma, Epithelioid | 1 | 2011 | 7 | 0.360 |
Why?
| | Skin Ulcer | 1 | 2011 | 14 | 0.360 |
Why?
| | Endometriosis | 1 | 2012 | 57 | 0.350 |
Why?
| | Cicatrix | 1 | 2012 | 69 | 0.350 |
Why?
| | Skin Diseases | 1 | 2012 | 149 | 0.320 |
Why?
| | Cesarean Section | 1 | 2012 | 224 | 0.320 |
Why?
| | Head and Neck Neoplasms | 1 | 2013 | 556 | 0.270 |
Why?
| | Biopsy | 4 | 2021 | 1075 | 0.260 |
Why?
| | Graft vs Host Disease | 3 | 2023 | 264 | 0.250 |
Why?
| | Glycogen | 1 | 2006 | 54 | 0.250 |
Why?
| | Immunohistochemistry | 3 | 2018 | 1715 | 0.240 |
Why?
| | Nevus, Epithelioid and Spindle Cell | 1 | 2026 | 14 | 0.240 |
Why?
| | Keratitis | 1 | 2025 | 20 | 0.230 |
Why?
| | Scleritis | 1 | 2025 | 28 | 0.230 |
Why?
| | Exome | 2 | 2017 | 227 | 0.230 |
Why?
| | Erythema Nodosum | 1 | 2025 | 6 | 0.230 |
Why?
| | Paresthesia | 1 | 2025 | 14 | 0.220 |
Why?
| | Hepatocytes | 1 | 2006 | 221 | 0.220 |
Why?
| | Eye Infections, Bacterial | 1 | 2025 | 44 | 0.220 |
Why?
| | Brain Neoplasms | 1 | 2014 | 1318 | 0.210 |
Why?
| | Fetomaternal Transfusion | 1 | 2023 | 10 | 0.200 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2013 | 1953 | 0.200 |
Why?
| | Humans | 29 | 2026 | 144261 | 0.200 |
Why?
| | HIV Infections | 1 | 2018 | 3079 | 0.200 |
Why?
| | Male | 18 | 2026 | 72035 | 0.190 |
Why?
| | Adult | 14 | 2026 | 40262 | 0.190 |
Why?
| | Proto-Oncogene Proteins | 2 | 2017 | 623 | 0.180 |
Why?
| | Skin | 3 | 2021 | 754 | 0.180 |
Why?
| | Skin Diseases, Vascular | 1 | 2021 | 8 | 0.170 |
Why?
| | Mastocytosis, Cutaneous | 1 | 2021 | 5 | 0.170 |
Why?
| | Mastocytosis | 1 | 2021 | 11 | 0.170 |
Why?
| | Embolism | 1 | 2021 | 48 | 0.170 |
Why?
| | Vasculitis | 1 | 2021 | 68 | 0.160 |
Why?
| | Biopsy, Needle | 2 | 2018 | 183 | 0.160 |
Why?
| | Mutation | 3 | 2017 | 4085 | 0.160 |
Why?
| | Exanthema | 2 | 2018 | 84 | 0.150 |
Why?
| | Carcinoma, Squamous Cell | 2 | 2013 | 641 | 0.140 |
Why?
| | Paint | 1 | 2017 | 9 | 0.130 |
Why?
| | Pregnancy Complications | 1 | 2023 | 592 | 0.130 |
Why?
| | Neurofibromin 1 | 1 | 2017 | 26 | 0.130 |
Why?
| | Carcinoma | 1 | 2019 | 227 | 0.130 |
Why?
| | Armadillo Domain Proteins | 1 | 2017 | 6 | 0.130 |
Why?
| | Proto-Oncogene Proteins c-kit | 1 | 2017 | 72 | 0.130 |
Why?
| | RNA Splicing Factors | 1 | 2017 | 64 | 0.130 |
Why?
| | Proto-Oncogene Proteins c-ret | 1 | 2017 | 40 | 0.120 |
Why?
| | Intraoperative Period | 1 | 2016 | 69 | 0.120 |
Why?
| | Mucous Membrane | 1 | 2017 | 127 | 0.120 |
Why?
| | Necrosis | 2 | 2021 | 244 | 0.120 |
Why?
| | Genes, erbB-1 | 1 | 2016 | 21 | 0.120 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2017 | 210 | 0.110 |
Why?
| | Phosphoproteins | 1 | 2017 | 343 | 0.110 |
Why?
| | Middle Aged | 9 | 2026 | 35762 | 0.100 |
Why?
| | 4-Nitroquinoline-1-oxide | 1 | 2013 | 9 | 0.100 |
Why?
| | Grape Seed Extract | 1 | 2013 | 29 | 0.100 |
Why?
| | Stilbenes | 1 | 2013 | 33 | 0.100 |
Why?
| | Tongue Neoplasms | 1 | 2013 | 25 | 0.100 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2017 | 433 | 0.100 |
Why?
| | Smad4 Protein | 1 | 2013 | 34 | 0.100 |
Why?
| | Oximes | 1 | 2013 | 26 | 0.100 |
Why?
| | Anticarcinogenic Agents | 1 | 2013 | 61 | 0.100 |
Why?
| | Carcinogens | 1 | 2013 | 122 | 0.100 |
Why?
| | MAP Kinase Kinase Kinases | 1 | 2013 | 70 | 0.100 |
Why?
| | Diagnosis, Differential | 2 | 2015 | 1487 | 0.100 |
Why?
| | Prognosis | 2 | 2018 | 4278 | 0.090 |
Why?
| | ras Proteins | 1 | 2013 | 150 | 0.090 |
Why?
| | Pyrimidinones | 1 | 2013 | 126 | 0.090 |
Why?
| | Analgesics, Opioid | 1 | 2021 | 1131 | 0.090 |
Why?
| | Neoplastic Stem Cells | 2 | 2013 | 412 | 0.090 |
Why?
| | Neoplasms, Hormone-Dependent | 1 | 2012 | 41 | 0.090 |
Why?
| | AMP-Activated Protein Kinases | 1 | 2013 | 190 | 0.090 |
Why?
| | Aged | 6 | 2019 | 25850 | 0.090 |
Why?
| | Mitotic Index | 1 | 2011 | 25 | 0.090 |
Why?
| | Imidazoles | 1 | 2013 | 254 | 0.090 |
Why?
| | Pyridones | 1 | 2013 | 198 | 0.090 |
Why?
| | Carcinoma in Situ | 1 | 2011 | 44 | 0.080 |
Why?
| | Neoplasm Metastasis | 1 | 2013 | 688 | 0.080 |
Why?
| | Carcinoma, Lobular | 1 | 2011 | 56 | 0.080 |
Why?
| | Treatment Outcome | 2 | 2018 | 11643 | 0.080 |
Why?
| | Antigens, CD20 | 1 | 2010 | 35 | 0.080 |
Why?
| | Receptors, Progesterone | 1 | 2012 | 356 | 0.080 |
Why?
| | Referral and Consultation | 1 | 2016 | 847 | 0.080 |
Why?
| | Bone Marrow Transplantation | 2 | 2010 | 294 | 0.080 |
Why?
| | Estrogens | 1 | 2012 | 380 | 0.070 |
Why?
| | Receptors, Estrogen | 1 | 2012 | 457 | 0.070 |
Why?
| | Risk Assessment | 1 | 2018 | 3637 | 0.070 |
Why?
| | Vipoma | 1 | 2008 | 1 | 0.070 |
Why?
| | Breast Neoplasms | 2 | 2012 | 2447 | 0.070 |
Why?
| | Adenocarcinoma | 1 | 2016 | 927 | 0.070 |
Why?
| | Female | 12 | 2023 | 77976 | 0.070 |
Why?
| | Hypertension, Portal | 1 | 2008 | 66 | 0.070 |
Why?
| | Transforming Growth Factor beta | 1 | 2010 | 479 | 0.060 |
Why?
| | Inclusion Bodies | 1 | 2006 | 27 | 0.060 |
Why?
| | Predictive Value of Tests | 1 | 2012 | 2111 | 0.060 |
Why?
| | Apoptosis | 2 | 2013 | 2430 | 0.060 |
Why?
| | Hepatitis B, Chronic | 1 | 2006 | 22 | 0.060 |
Why?
| | Gene Fusion | 1 | 2026 | 29 | 0.060 |
Why?
| | Cytoplasm | 1 | 2006 | 269 | 0.060 |
Why?
| | Atrophy | 1 | 2025 | 200 | 0.060 |
Why?
| | Anti-Bacterial Agents | 1 | 2015 | 1906 | 0.050 |
Why?
| | Tomography, Optical Coherence | 1 | 2025 | 264 | 0.050 |
Why?
| | High-Throughput Nucleotide Sequencing | 2 | 2017 | 549 | 0.050 |
Why?
| | Drug Therapy, Combination | 1 | 2025 | 1044 | 0.050 |
Why?
| | Lung Neoplasms | 1 | 2016 | 2637 | 0.050 |
Why?
| | DNA-Binding Proteins | 1 | 2010 | 1497 | 0.050 |
Why?
| | Carcinogenesis | 2 | 2013 | 229 | 0.040 |
Why?
| | Purpura | 1 | 2021 | 18 | 0.040 |
Why?
| | Tablets | 1 | 2021 | 41 | 0.040 |
Why?
| | Fasciotomy | 1 | 2021 | 23 | 0.040 |
Why?
| | Tumor Cells, Cultured | 2 | 2013 | 919 | 0.040 |
Why?
| | Injections, Intravenous | 1 | 2021 | 200 | 0.040 |
Why?
| | Foreign-Body Reaction | 1 | 2021 | 36 | 0.040 |
Why?
| | Triazines | 1 | 2021 | 49 | 0.040 |
Why?
| | Fingers | 1 | 2021 | 107 | 0.040 |
Why?
| | Fatal Outcome | 1 | 2021 | 307 | 0.040 |
Why?
| | Pancreatic Neoplasms | 1 | 2008 | 918 | 0.040 |
Why?
| | Foreign Bodies | 1 | 2021 | 107 | 0.040 |
Why?
| | Pyrroles | 1 | 2021 | 217 | 0.040 |
Why?
| | Fetus | 1 | 2023 | 803 | 0.040 |
Why?
| | Retrospective Studies | 1 | 2016 | 17009 | 0.030 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2023 | 674 | 0.030 |
Why?
| | Patient Compliance | 1 | 2021 | 585 | 0.030 |
Why?
| | Pyrazoles | 1 | 2021 | 509 | 0.030 |
Why?
| | Gene Rearrangement | 1 | 2017 | 155 | 0.030 |
Why?
| | Lung Transplantation | 1 | 2019 | 338 | 0.030 |
Why?
| | DNA Copy Number Variations | 1 | 2016 | 183 | 0.030 |
Why?
| | DNA Mutational Analysis | 1 | 2016 | 405 | 0.030 |
Why?
| | Aged, 80 and over | 2 | 2017 | 8243 | 0.030 |
Why?
| | Side-Population Cells | 1 | 2013 | 8 | 0.030 |
Why?
| | alpha Catenin | 1 | 2013 | 11 | 0.030 |
Why?
| | In Situ Nick-End Labeling | 1 | 2013 | 121 | 0.030 |
Why?
| | Cell Dedifferentiation | 1 | 2013 | 32 | 0.030 |
Why?
| | Tongue | 1 | 2013 | 76 | 0.020 |
Why?
| | Neoplasm Transplantation | 1 | 2013 | 251 | 0.020 |
Why?
| | Sequence Deletion | 1 | 2013 | 193 | 0.020 |
Why?
| | CD24 Antigen | 1 | 2012 | 18 | 0.020 |
Why?
| | Breast Neoplasms, Male | 1 | 2012 | 29 | 0.020 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2013 | 253 | 0.020 |
Why?
| | Hyaluronan Receptors | 1 | 2012 | 102 | 0.020 |
Why?
| | Substance-Related Disorders | 1 | 2021 | 1054 | 0.020 |
Why?
| | Mice, Nude | 1 | 2013 | 682 | 0.020 |
Why?
| | Precision Medicine | 1 | 2016 | 456 | 0.020 |
Why?
| | RNA Interference | 1 | 2013 | 476 | 0.020 |
Why?
| | Mutation, Missense | 1 | 2013 | 340 | 0.020 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2013 | 219 | 0.020 |
Why?
| | Mice, SCID | 1 | 2012 | 369 | 0.020 |
Why?
| | Tamoxifen | 1 | 2012 | 217 | 0.020 |
Why?
| | Mice | 3 | 2013 | 18329 | 0.020 |
Why?
| | Child, Preschool | 1 | 2006 | 11774 | 0.020 |
Why?
| | Tumor Burden | 1 | 2012 | 319 | 0.020 |
Why?
| | Computational Biology | 1 | 2016 | 680 | 0.020 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2012 | 194 | 0.020 |
Why?
| | Cluster Analysis | 1 | 2012 | 519 | 0.020 |
Why?
| | Mice, Inbred NOD | 1 | 2012 | 610 | 0.020 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2016 | 881 | 0.020 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2012 | 758 | 0.020 |
Why?
| | Pregnancy | 1 | 2023 | 7180 | 0.020 |
Why?
| | Gene Regulatory Networks | 1 | 2012 | 318 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2017 | 3592 | 0.020 |
Why?
| | Microfilament Proteins | 1 | 2010 | 135 | 0.020 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2012 | 928 | 0.020 |
Why?
| | Calcium-Binding Proteins | 1 | 2010 | 219 | 0.020 |
Why?
| | Adrenalectomy | 1 | 2008 | 71 | 0.020 |
Why?
| | Splenectomy | 1 | 2008 | 65 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2013 | 2182 | 0.020 |
Why?
| | Acantholysis | 1 | 2007 | 2 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2017 | 5389 | 0.020 |
Why?
| | Pancreaticoduodenectomy | 1 | 2008 | 135 | 0.020 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2013 | 1455 | 0.020 |
Why?
| | MicroRNAs | 1 | 2013 | 700 | 0.020 |
Why?
| | Animals | 3 | 2013 | 38030 | 0.020 |
Why?
| | Child | 1 | 2006 | 22537 | 0.020 |
Why?
| | Transplantation, Homologous | 1 | 2007 | 415 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2013 | 2494 | 0.010 |
Why?
| | Transcriptome | 1 | 2012 | 1044 | 0.010 |
Why?
| | Pancreatectomy | 1 | 2008 | 285 | 0.010 |
Why?
| | B-Lymphocytes | 1 | 2010 | 876 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2013 | 5988 | 0.010 |
Why?
| | RNA, Messenger | 1 | 2010 | 2829 | 0.010 |
Why?
| | Young Adult | 1 | 2017 | 13990 | 0.010 |
Why?
| | Signal Transduction | 1 | 2012 | 5221 | 0.010 |
Why?
| | Biomarkers | 1 | 2010 | 4254 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 1 | 2008 | 2730 | 0.010 |
Why?
|
|
Wisell's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|